Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-25T05:34:11.530Z Has data issue: false hasContentIssue false

9 - The drug treatment of Parkinson's disease in elderly people

Published online by Cambridge University Press:  24 November 2009

Jolyon Meara
Affiliation:
University of Wales College of Medicine
William C. Koller
Affiliation:
Kansas University Medical Center
Get access

Summary

Introduction

The goal of medical management of Parkinson's disease (PD) is to control signs and symptoms for as long as possible while minimizing side effects. Medical therapy generally provides good control of symptoms for 4 to 6 years, though disability continues to progress despite best medical management, and many patients develop long-term complications. Such complications include motor fluctuations and dyskinesia associated with long-term levodopa therapy (Chase et al. 1993). Other common causes of disability in late stage disease include postural instability and dementia.

A key consideration in the treatment of elderly patients is that they are more susceptible to side effects from medication. Older people are more likely than younger individuals to be taking more prescribed and over the counter medication for a range of diseases. Medication prescribed for one condition can worsen another and side effects from medication can be mistaken as a new disease process and lead to further unnecessary prescribing (Williamson 1978). Cognitive impairment and delirium, both of which commonly develop as side effects of drug therapy, reduce compliance with drug treatment.

As people live longer the prevalence of PD will increase. PD is a significant risk factor for admission to nursing homes. Over 50% of prevalent cases of PD in one epidemiological study in France were living in nursing homes (Tison et al. 1994). Hallucinations are a particular factor that increases the risk of admission to nursing homes in PD and in many cases this will be related to the drug therapy prescribed for PD (Goetz and Stebbins 1995).

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×